ALTERNATIVE APPROACHES TO DEAL WITH LONG COVID ILLNESS: AN AYURVEDIC NARRATIVE REVIEW (2025)
“While anecdotal evidence and small studies show promise, the current body of research on Ayurveda for Long COVID is limited.”
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for overall symptoms.
1 outcome rated · see each below
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 5 findings, all C.
5 outcomes rated · see each below
Preventing long COVID: C Might help, very uncertain
Based on the strongest evidence, the randomised trial and compared with another group, not randomised (very low certainty): 6 of 7 findings are C.
6 outcomes rated · see each below
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, Ayurveda might help some people, but research can’t show it yet. For ME/CFS, Ayurveda might help some people, but research can’t show it yet. For preventing long COVID, Ayurveda might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (2 in all); not all results were tested against chance.
Studies with no comparison group2 studies · 2 people with results (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of ayurveda on overall symptoms in long COVID. Improvement · very low certainty C
A SINGLE CASE STUDY OF POST COVID COMPLICATIONS: AN AYURVEDIC APPROACH (2022)
PRAGMATIC APPROACH OF AYURVEDA IN LONG-COVID MANAGEMENT – A CASE STUDY: Array (2022)
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · at baseline and at the end of 2 months · Two teaspoons, twice daily, after breakfast and dinner (few people)
Fatigue improved.
The evidence is very uncertain about the effect of ayurveda on fatigue in ME/CFS. Improvement · very low certainty C
Ayurvedic treatment of chronic fatigue syndrome--a case report. (2005)
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · at baseline and at the end of 2 months · Two teaspoons, twice daily, after breakfast and dinner (few people)
Pain improved.
The evidence is very uncertain about the effect of ayurveda on pain in ME/CFS. Improvement · very low certainty C
Ayurvedic treatment of chronic fatigue syndrome--a case report. (2005)
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · at baseline and at the end of 2 months · Two teaspoons, twice daily, after breakfast and dinner (few people)
Sleep improved.
The evidence is very uncertain about the effect of ayurveda on sleep in ME/CFS. Improvement · very low certainty C
Ayurvedic treatment of chronic fatigue syndrome--a case report. (2005)
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · at baseline and at the end of 2 months · Two teaspoons, twice daily, after breakfast and dinner (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of ayurveda on daily functioning in ME/CFS. Improvement · very low certainty C
Ayurvedic treatment of chronic fatigue syndrome--a case report. (2005)
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · at baseline and at the end of 2 months · Two teaspoons, twice daily, after breakfast and dinner (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of ayurveda on overall symptoms in ME/CFS. Improvement · very low certainty C
Ayurvedic treatment of chronic fatigue syndrome--a case report. (2005)
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (99 in all).
The randomised trial99 randomised · 7 days · Two tablets, 12 hourly after meals
Breathlessness improved more than in the comparison group.
The evidence is very uncertain about the effect of ayurveda on breathlessness later, when given during acute COVID. Improvement · very low certainty C
Compared with another group, not randomised50 in the study · Baseline, day 14, day 28, and day 60
Breathlessness improved more than in the comparison group.
The evidence is very uncertain about the effect of ayurveda on breathlessness later, when given during acute COVID. Improvement · very low certainty C
The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen. (2022)
Cochran-Mantel-Haenszel test was applied, factoring in baseline variations.
The participants were allocated based on their own voluntary choice into either of the groups.
The analysis included available subjects at each follow-up visit, incorporating data from dropouts.
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (99 in all).
The randomised trial99 randomised · 7 days · Two tablets, 12 hourly after meals
Anxiety improved more than in the comparison group.
The evidence is very uncertain about the effect of ayurveda on anxiety later, when given during acute COVID. Improvement · very low certainty C
The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen. (2022)
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (99 in all).
The randomised trial99 randomised · 7 days · Two tablets, 12 hourly after meals
Fatigue improved more than in the comparison group.
The evidence is very uncertain about the effect of ayurveda on fatigue later, when given during acute COVID. Improvement · very low certainty C
The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen. (2022)
Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).
Compared with another group, not randomised50 in the study · Baseline, day 14, day 28, and day 60
Smell and taste loss improved more than in the comparison group.
The evidence is very uncertain about the effect of ayurveda on smell and taste loss later, when given during acute COVID. Improvement · very low certainty C
Cochran-Mantel-Haenszel test was applied, factoring in baseline variations.
The participants were allocated based on their own voluntary choice into either of the groups.
The analysis included available subjects at each follow-up visit, incorporating data from dropouts.
Why this grade: Uncertain, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (99 in all); helped less than study group, an active treatment; not a sign of harm.
The randomised trial99 randomised · 7 days · Two tablets, 12 hourly after meals
Pain improved less than with the comparison treatment.
Ayurveda helped pain less than study group in the one comparison. Uncertain · very low certainty –
The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen. (2022)
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (99 in all).
The randomised trial99 randomised · 7 days · Two tablets, 12 hourly after meals
Overall symptoms improved more than in the comparison group.
The evidence is very uncertain about the effect of ayurveda on overall symptoms later, when given during acute COVID. Improvement · very low certainty C
Compared with another group, not randomised50 in the study · Baseline, day 14, day 28, and day 60
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of ayurveda on overall symptoms later, when given during acute COVID. Little or no difference · very low certainty D
The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen. (2022)
Cochran-Mantel-Haenszel test was applied, factoring in baseline variations.
The participants were allocated based on their own voluntary choice into either of the groups.
The analysis included available subjects at each follow-up visit, incorporating data from dropouts.
| Side effect | Studies that reported it |
|---|---|
| Nausea or stomach upset | 1 study |
Reviews pool earlier studies. Each shows when it was published and how far its search went.
“While anecdotal evidence and small studies show promise, the current body of research on Ayurveda for Long COVID is limited.”
This extension phase study followed patients who had taken part in an open label prospective randomized clinical trial of an add-on Ayurveda regimen at a dedicated COVID Hospital in Pune, Maharashtra, India. All 99 patients who participated in the trial were interviewed after informed consent, over 9 months after discharge from hospital. The regimen was Tab. Dasamoolkaduthrayadi Kashaya plus Tab. Guluchyadi Kwatham, two tablets of each administered 12 hourly after meals for 7 days, along with conventional standard of care; the control group received conventional standard of care. Table 1, titled 9 months Post COVID symptoms/illness observations, reports a study group of 60 and a control group of 39. Fatigue was recorded in 7 (11.66%) and 5 (12.82%), exertional dyspnea in 2 (3.33%) and 5 (12.82%), lower leg pain in 2 (3.33%) and 0, and the total row reads 12 (20%) and 17 (43.58%). Median duration of post COVID symptoms/illness was 25 days (range of 7 days–60 days) in the study group and 30 days (range 15 days–180 days) in the control group. The abstract states that no additional late effects or symptoms or complications which were known in Post COVID phase were observed in the study group as compared to the control group. The paper also reports no Herb-Drug Interaction with the conventional standard of care. Withdrawals for harms were not reported. The authors state that the consequences observed over the 9 months cannot be attributed exclusively as post COVID events.
This case study reports one 31-year-old female homemaker from New Delhi with post-COVID anxiety with depression persisting for nearly 12 months after COVID-19. She had taken anxiolytic and antidepressant medications for the past ten months. She was admitted for 15 days and received Shirodhara with Balashwagandhadi taila for 45 minutes per day for 14 days as an add-on to conventional medications (Paroxetine 25 mg once daily, Propranolol 20 mg twice daily, Omeprazole 20 mg once daily, Clonazepam 0.5 mg at bedtime). There was no comparison group. Assessments were at baseline, 8th day, 15th day and 30th day. HAM-A fell from 42 to 10, HAM-D from 23 to 6, PHQ-9 from 24 to 1, and QOLS rose from 59 to 79. Serum cortisol was 3.09 μg/dL at baseline and 11.76 μg/dL on the 15th day. After Shirodhara, the psychiatry consultant reduced conventional medications: Propranolol was tapered from 20 mg twice daily to 20 mg once daily, Clonazepam 0.5 mg at bedtime was changed to as-needed use, and Omeprazole was discontinued. No adverse effects were reported during or after the therapy. At a telephonic follow-up in June 2026, the patient reported sustained improvement and that all conventional medications had been discontinued. The authors state that these findings require validation through larger studies with long-term follow-up.
This single case study reported on a 42-year-old man who presented on 25/6/2021 to the Out Patient Department of Govt. Ayurved Hospital Moti Chohatta, Udaipur with post-COVID complications that began after 25 days of testing Covid positive. His symptoms included left lower leg swelling, skin rashes with itching on the swollen leg, bilateral chest pain, shortness of breath, and general body weakness. He received Ayurvedic management for 23 days, consisting of Rajah pravartni vati, Mahavaatvidhvansak ras, Godanti bhasma, Trikatu choorna, Manjishtha choorna, Avipattikar choorna, Kaishor guggulu, Mahamarichyadi tail for local application, Vasakantakari kwatha, and Shothahar kwatha. No comparison group or concomitant medications were reported. Outcomes were post-COVID complications and symptoms; laboratory markers D-Dimer and CRP were also reported. After 23 days, the authors stated the patient was fully recovered and got relief in symptoms. Harms and withdrawals were not reported. The authors declared no source of support and no conflict of interest. No limitations were stated.
This is a single-patient case study asking whether an Ayurvedic regimen could manage Long-COVID. It included one male patient diagnosed as Long-COVID who reported to the author’s OPD with low-grade fever, fatigue, multiple joint pain and muscle pain, and worsening after physical or mental activity. The patient received Suvarnamalini Vasant Ras, Drakshadi Kashayam and Guduchisiddha Ghrut, plus Abhyanga with Chandanadi Taila. The treatment lasted over the period of three months. There was no comparison group, no randomisation and no crossover; the report compares the patient only before and after treatment. The recorded outcome was complete relief, reported as “The treatment over the period of three months resulted in complete relief.” No baseline or follow-up scores, no statistical test, no side effects, no harms and no withdrawals were reported. The authors conclude: “Thus the Ayurvedic treatment was found to be effective in managing Long-COVID.” Limitations stated by the authors: not reported.
This case report describes one 39-year-old female software technical support specialist with chronic fatigue syndrome, diagnosed after clinical and laboratory assessment and 1994 disease criteria. She received Ayurvedic herbal medicines for 2 months: Stress Guard one capsule twice daily with warm milk, Shankhpushpi syrup two teaspoons twice daily after breakfast and dinner, and Chyavanprash two teaspoons once a day at 7 AM, plus breathing exercises (pranayama) and diet and lifestyle advice. There was no comparison group; outcomes were collected at baseline and at the end of 2 months. The total MFIS score was 63 at baseline and 27 at the end of 2 months; physical subscale 27 to 12, cognitive 30 to 12, and psychosocial 6 to 2. Fatigue was 3-6 hours every day at baseline and less than 3 hours per day at the end of 2 months; neck pain, throat irritation, and bloating disappeared; 8 hours sleep was now refreshing and she was not feeling sleepy during the day. A follow-up phone call at the end of 3.5 months found she was continuing to feel better. Side effects and withdrawals were not reported. The authors note the improvement could have been the result of other factors, such as the natural course of the disease or a placebo effect, and call for larger studies and randomized controlled trials.
This case study explored Ayurvedic treatment, dietary modifications, and yogic interventions for CFS, described as a debilitating disorder with prolonged unexplained fatigue, cognitive dysfunction, sleep disturbances, and musculoskeletal pain, and limited conventional options. The study involved a single 38-year-old male patient diagnosed with CFS. He underwent comprehensive assessment using laboratory tests, hormonal profiling, and imaging techniques. The intervention combined Ayurvedic formulations, a customized diet plan, and a structured yoga regimen including pranayama and meditation. The text reports no comparison group, no randomisation, and no treatment duration. Efficacy was evaluated using subjective and objective measures before and after the intervention. The authors report significant improvement in fatigue levels and overall quality of life. No side effects, withdrawals, or harms are reported. The paper does not report a follow-up period. The authors conclude that the combination proved effective in alleviating CFS symptoms and state that further research with larger sample sizes is warranted to establish standardized protocols.
This single case report describes a 20-year-old female with post covid parosmia after SARS-CoV-2 infection; the setting is not reported. There was no comparison group. Treatment was an integrative Ayurveda and Traditional Chinese Acupuncture approach: Nasya with Shadbindu taila, eight Bindu (4 ml) into each nostril in the morning for seven days; acupuncture in the afternoon for 20 min duration for seven days; Naradiya laxmivilasa rasa one tablet (250 mg) orally thrice daily after food for one month; and Pratimarsha nasya with Shadbindu taila, two Bindu (1 ml) into each nostril thrice daily from day eight to the end of four months. Outcomes were Indian Smell identification test score, VAS for parosmia, severity analysis, and quality of life. ISIT was zero before treatment, four on day seven, eight after one month, and ten after four months. VAS was ten before treatment and zero on day seven, after one month, and after four months. Severity analysis was severe alterations before treatment and normal at all follow-up points. The paper reports considerable improvement in quality of life in terms of sleep, food intake and psychological stress, and the authors inferred there would be no side effects by this unique integrative approach. No limitations are stated.
This case report describes one male subject, age 53 years, with post covid 19 symptoms. The abstract states he visited with complaints and had a history of covid positive and allopathy treatment; the recorded data identify the condition as long COVID and the design as a case report. He was treated with Ashwagandha ghanavati, Sanshamani vati, Chyawanaprasha and Shadanga paniya along with pathyapathya (wholesome dietary and behavioral regimen) for 30 days. There was no comparison group, no randomisation and no blinding reported. The recorded outcome is 'symptoms were reduced and improvement was seen in patient's condition' after 30 days; no baseline or follow-up scores, no spread, no p value and no statistical method are reported. One patient was enrolled, started and analysed, per the recorded data. The abstract does not report harms, side effects or withdrawals from harms. Limitations are not reported in the abstract. The authors conclude: 'It may be concluded from this case that the use of Ayurvedic formulations is useful in the treatment of post-covid symptoms.'
This narrative review asked how Ayurvedic approaches might address Long COVID (PASC). It searched PubMed, Scopus and Google Scholar for publications from January 2020 to September 2025; 156 results were obtained, 62 articles were selected for full-text review, and 29 met inclusion criteria for final synthesis. The review describes case reports and one prospective, controlled pilot study. The cases included a 53-year-old male with persistent Long COVID symptoms, a 20-year-old female with post-viral olfactory dysfunction (parosmia), and a 71-year-old patient with severe persistent post-COVID symptoms. Treatments described included Ashwagandha Ghanavati, Sanshamani vati, Chyawanaprasha, Shadanga paniya, Shadbindu taila nasya, Naradiya laxmivilasa rasa, Ayurvedic dietary guidelines, herbal/herbomineral formulations, Pranayama, breathing exercises and meditation. In the 71-year-old, clinical condition improved within three weeks and radiological findings within six weeks. Kumar et al. compared add-on personalised Ayurveda with standard of care in hospitalised mild to moderate COVID-19 patients with Type 2 Diabetes; among 13 assessed symptoms, cough, general weakness and sore throat showed statistically significant improvement with add-on Ayurveda. Other cases reported subjective or effective improvement. No Ayurvedic side-effect counts, worsening or withdrawals were reported. The authors state evidence is limited and call for rigorous large-scale controlled trials.
This systematic review asked what evidence exists on interventions for rehabilitation for COVID-19-related limitations of functioning in adults with COVID-19 or post COVID-19 condition (PCC). It included 53 RCTs with 3882 randomized participants; included adults were hospitalized or managed at home, and the review covered non-severe, severe, critical COVID-19 and PCC. Interventions were compared with usual care, sham/placebo, no treatment, or another active intervention; duration was not reported. Outcomes covered body functions, activities and participation, quality of life, and adverse events. The review synthesized evidence narratively. It reports that the effect of breathing and strengthening exercise programs on dyspnea and physical exercise capacity compared to no treatment in non-severe COVID-19 patients is uncertain. Multicomponent telerehabilitation may slightly increase physical exercise capacity compared to educational intervention in adults with PCC, but uncertainty remains about its effect on lung function and physical exercise capacity compared to no treatment; it reported no evidence of an effect on FVC and FEV1/FVC% for multicomponent telerehabilitation compared to no treatment in PCC. The effect of inspiratory muscle training on maximal inspiratory pressure compared to no treatment in adults with PCC is uncertain. For harms, four grouped studies and fourteen studies reported no adverse events; five and three mild adverse events (transient skin redness) occurred in active HD-tDCS and sham groups, respectively; one person in the sham group presented symptom exacerbation; olfactory training had two (0.8%) headache reports and one (0.4%) worsening parosmia report. The authors state they cannot provide robust suggestions for practice.
Why: to see whether treatments given during acute or early post-acute Covid-19 prevent post Covid-19 condition (symptoms ≥12 weeks after onset). Who: a systematic review of 31 studies; the searches were run on 28 July 2021 for the intervention question. Several preventive-intervention studies were retrospective controlled cohorts, and most were in hospitalized patients. What was given and compared: corticosteroids, antibiotics, hydroxychloroquine, therapeutic anticoagulation, zinc, intravenous immunoglobulin, oseltamivir, ganciclovir, human umbilical cord mesenchymal stem cells (12 vs 29), an ayurvedic formulation (30 vs 30), Chinese medicine (64 vs 32), telerehabilitation (14 vs 13), cognitive-motor therapy (42), photobiomodulation (5 vs 5), and screening with referrals. Found: certainty was very low throughout. Examples: with stem cells, adverse events were 0 and serious adverse events 0; with the ayurvedic formulation, fatigue was 1 (5%) vs 6 (26.1%); with photobiomodulation, respiratory symptoms were 0/5 (0%) vs 4/5 (80%); with telerehabilitation, adverse events were none reported; with Chinese medicine there was no significant difference in the improvement rates of symptoms, including fatigue, between the two groups (p > .05); antibiotic use was associated with salivary gland ectasia, aOR 8.34 (95% CI, 1.47–158.19).
This review examined Ayurveda approaches to post COVID management. The authors searched textual references and research articles on post-COVID symptoms using keywords. No setting, enrolled participant count, or own comparison group was reported; the paper is a review, not a trial. It summarizes Ayurveda modalities such as Ayush Kadha, Samshamani vati or Guduchi, Ashwagandha, Amla, Mulethi, warm milk with haldi, gargling, Chyawanprash, Yogasana, Pranayama, and meditation. For named studies, the review reports that in a clinical trial by Kataria S et al., an adjuvant formulation of Guduchi and Pippali shortened hospital stay and enhanced recovery time, and the adjuvant Ayurveda group had greater overall sense of well-being and activity levels during the three-month follow-up after discharge. In a clinical Study by Gupta K and Singhal A, patients with post COVID syndrome received Ashwagandha Pak with Pranayam or Vardhman Pippali Rasayan with Pranayam; the review reports complete improvement in 50% patients, moderate improvement in 35.2% patients and mild improvement in 11.76% of patients, with more results of Vardhman Pippali Rasayana than Ashwagandha Kalp. The review also states that about 7 studies of Guduchi as prophylactic care on about 1.33 lakh people reported managing asymptomatic COVID without any side effects. The authors state a need for more research.